Tecartus

Phase 2Small molecule

HH. Lee Moffitt Cancer Center and Research Institute

Tecartus is one of 30 small molecule programs targeting CAR T Cell Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CAR T Cell TherapyActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaRecruiting

CAR T Cell TherapyPhase 2

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

27 competitors in B-Cell Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Fludara

7 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 4

Blincyto

Amgen

Phase 2

4 5

Tisagenlecleucel

Novartis

Phase 2

1 6

CTL019

Novartis

Phase 3

2 7

Erbitux

IImclone

Phase 1

1 8

YK012

EExcyte Biopharma Ltd

Phase 2

1 9

Inaticabtagene Autoleucel

JJuventas Cell Therapy Ltd.

Phase 2

1 10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

CAR T Cell Therapy

NCT03642626

Q4 2028

Phase 2Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT06144606

Clinical

Trials by Indication[1]

CAR T Cell Therapy1 trial

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03642626·150 enrolled

B-cell acute lymphoblastic leukemia1 trial

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06144606·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tecartus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tecartus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tecartus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — H. Lee Moffitt Cancer Center and Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HH. Lee Moffitt Cancer Center and Research Institute

Tecartus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

CAR T Cell Therapy1 trial

B-cell acute lymphoblastic leukemia1 trial

References

Drug Info

Quick Facts

Related News